Name: Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab)
SKU: CROSSAB-H303
Rating: 5 (1 reviews)

Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab) is designed to be expressed as four chains with knobs-into-holes mutations and domain crossover. After one or multi-steps purification, high-purity antibody can be obtained. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD89 & EGFR

Type

CrossMab

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC)Solid tumors

Host Animal 1

Human

Host Animal 2

Human

Targets

Target 1

CD89

Gene ID

2204

UniProt ID

P24071

Alternative Names

FcαRI; FCAR; Fc fragment of IgA, receptor for; CD89; FcalphaRI; immunoglobulin alpha Fc receptor; Fc alpha receptor

Target 2

EGFR

Gene ID

1956

UniProt ID

P00533

Alternative Names

EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab) (CROSSAB-H303). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD89 x Anti-EGFR Bispecific Antibody (CrossMab) (CAT#: CROSSAB-H303)

Specifications

Targets

Customer Reviews and Q&As